Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
OrbiMed entities filed Amendment No. 4 to update their ownership in Enliven Therapeutics, Inc. common stock. The filing reports that OrbiMed Advisors LLC may be deemed to beneficially own 7,634,630 shares, representing 10.93% of Enliven’s outstanding common stock.
This percentage is based on 69,822,929 shares outstanding, as stated in Enliven’s Rule 424(b)(5) prospectus. The amendment notes that, due to recent transactions and an increase in shares outstanding, the OrbiMed group’s beneficial ownership decreased by more than 1%.
The position is held through several investment vehicles: OrbiMed Private Investments VII, LP with 7,388,902 shares (10.58%), OrbiMed Genesis Master Fund, L.P. with 245,728 shares (0.35%), and The Biotech Growth Trust PLC with 31,132 shares (0.04%). OrbiMed-related entities share or exercise voting and investment power over these holdings, while individual OrbiMed principals disclaim beneficial ownership. The group states it may buy more, hold, or sell shares over time but has no specific corporate action plans.
Enliven Therapeutics filed a Form 144 reporting the proposed sale of 18,054 shares of Common Stock through Jefferies LLC, dated 06/17/2026. The notice lists three lots tied to option exercises: 7,090, 3,000, and 7,964 shares with exercise dates shown as 08/09/2022, 12/13/2024, and 03/04/2025, respectively.
The filing identifies Jefferies LLC at 520 Madison Ave as the broker-dealer and shows an aggregate value field of $768,197.70 on the cover line. The filing is a routine Section 16 disposition notice for resale of shares previously acquired by option exercise.
Enliven Therapeutics priced an upsized underwritten public offering of 8,933,334 shares of common stock at $37.50 per share and pre-funded warrants to purchase up to 1,733,333 shares at $37.499 each. All securities are being sold by the company, with expected gross proceeds of about $400.0 million.
Net proceeds are expected to be approximately $376.0 million, or $432.4 million if underwriters fully exercise a 1,600,000-share option. The offering, made off an effective Form S-3ASR shelf, is expected to close on or about June 15, 2026, subject to customary conditions. The pre-funded warrants are exercisable immediately at $0.001 per share and include ownership caps between 4.99% and 19.99%.
Enliven Therapeutics is offering 8,933,334 shares of common stock and pre-funded warrants to purchase 1,733,333 shares. The public offering price per share is $37.50 and each pre-funded warrant has an exercise price of $0.001. Delivery is expected on or about June 15, 2026. Net proceeds to the company are estimated at approximately $376.0M before expenses, or $432.4M if the underwriters’ 30-day option for an additional 1,600,000 shares is exercised in full. The prospectus supplement notes an ownership limitation on exercises (default 4.99%, holder-elected 9.99%, increaseable up to 19.99% with notice) and that pre-funded warrants are not listed and have no established trading market. The company expects to use proceeds to advance ELVN-001 clinical development and for working capital and general corporate purposes.
Enliven Therapeutics is offering $250,000,000 of common stock and pre-funded warrants as part of a shelf offering. The prospectus supplement states the offering size is $250,000,000 and that pre-funded warrants will have an exercise price of $0.001 per share.
The document discloses 60,889,655 shares outstanding as of March 31, 2026, a historical net tangible book value of $453.4 million (or $7.45 per share as of March 31, 2026), and an underwriters’ option to purchase up to an additional $37,500,000. Net proceeds are described as intended to fund ELVN-001 clinical development, initial commercial readiness and general corporate purposes, and management believes available capital will fund operations into 2030.
Enliven Therapeutics announced updated positive Phase 1 data for its CML drug candidate ELVN-001 and reported key outcomes from an End-of-Phase 1 meeting with the FDA. In Phase 1b, overall major molecular response (MMR) reached 54% in evaluable patients and 61% in the 80 mg once-daily cohort by week 24, with 100% of patients who achieved MMR maintaining it. Response rates by 24 weeks were higher in patients treated earlier in their TKI sequence, including those previously on asciminib. The safety profile was described as favorable and consistent with ELVN-001’s high selectivity, based on 161 enrolled patients and a median treatment duration of 35 weeks. Enliven and the FDA reached alignment on 80 mg once daily as the recommended Phase 3 dose and on a second-line-or-later patient population for the planned ENABLE-2 pivotal trial, which the company expects to initiate in the second half of the year.
Enliven Therapeutics, Inc. reported the results of its annual stockholder meeting and an amendment to its charter. Stockholders approved increasing authorized common stock from 100,000,000 to 200,000,000 shares, and the company filed a Certificate of Amendment making total authorized capital 210,000,000 shares.
Two Class III directors, Richard Fair and Lori Kunkel, were elected to terms ending at the 2029 meeting. Stockholders ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, approved executive compensation on an advisory basis, and supported holding future say‑on‑pay votes every year.